Orion has been granted a patent for compounds that inhibit cytochrome P450 monooxygenase 11A1 (CYP11A1), with potential applications in treating androgen receptor-dependent conditions, such as prostate cancer. The patent includes various specific chemical structures and their pharmaceutically acceptable salts. GlobalData’s report on Orion gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Orion, Cancer treatment biomarkers was a key innovation area identified from patents. Orion's grant share as of June 2024 was 57%. Grant share is based on the ratio of number of grants to total number of patents.
The patent US12030871B2 encompasses a series of novel compounds characterized by specific chemical structures, primarily featuring a 4H-pyran-4-one core linked to various piperidine and isoindoline moieties. These compounds are designed to interact with steroid receptors, particularly androgen receptors, and are proposed for the treatment of steroid receptor-dependent conditions, including various forms of cancer. Notably, the claims detail methods for administering these compounds to treat conditions such as castration-resistant prostate cancer (CRPC), highlighting their potential therapeutic applications. The patent also includes provisions for pharmaceutical compositions that combine these compounds with acceptable carriers and other active ingredients, enhancing their efficacy.
In addition to the compounds themselves, the patent outlines methods for treatment that may involve the concurrent administration of glucocorticoids, mineralocorticoids, and a range of anti-cancer agents. These agents include non-steroidal androgen receptor antagonists, steroidogenesis inhibitors, and various chemotherapeutic agents, among others. The comprehensive nature of the claims suggests a multifaceted approach to treating steroid receptor-dependent diseases, particularly in oncology, where the modulation of steroid receptor activity can be crucial for effective therapy. The patent thus presents a significant advancement in the development of targeted treatments for hormone-related cancers.
To know more about GlobalData’s detailed insights on Orion, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
